Cargando…

New Frontiers: The Role of CAR T-Cell Therapy in Multiple Myeloma

Multiple myeloma remains the second most common hematologic malignancy, and relapse rates are high, with refractory disease common with each relapse. Chimeric antigen receptor (CAR)–modified T cells are a promising new treatment, and at JADPRO Live Virtual 2021, presenters compared pivotal trials in...

Descripción completa

Detalles Bibliográficos
Autores principales:	McClanahan, Alli, Spychalla, Megan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Harborside Press LLC 2022
Materias:	Meeting Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9126344/ https://www.ncbi.nlm.nih.gov/pubmed/35663181 http://dx.doi.org/10.6004/jadpro.2022.13.3.30

Ejemplares similares

BCMA-Directed CAR T Cells in Relapsed Refractory Multiple Myeloma: Highlights From SOHO 2021
Publicado: (2022)

New Frontiers in the Treatment of Multiple Myeloma
por: Hwang, Janice Jin, et al.
Publicado: (2006)

Next frontiers in CAR T-cell therapy
por: Brown, Christine E, et al.
Publicado: (2016)

European Myeloma Network perspective on CAR T-cell therapies for multiple myeloma
por: Bruno, Benedetto, et al.
Publicado: (2021)

B-cell maturation antigen (BCMA) in multiple myeloma: the new frontier of targeted therapies
por: Sanchez, Larysa, et al.
Publicado: (2021)

Advanced Imaging in Multiple Myeloma: New Frontiers for MRI
por: Torkian, Pooya, et al.
Publicado: (2022)

The fungal frontier
por: Blankenship, Jill R, et al.
Publicado: (2007)

CAR T-cell therapy in multiple myeloma: more room for improvement
por: Teoh, Phaik Ju, et al.
Publicado: (2021)

New frontiers in cancer therapy: the 11th International Meeting of the Asian Clinical Oncology Society (ACOS)
por: Chou, Hung-Hsueh
Publicado: (2014)

At the frontiers of surgery: review
por: Upile, Tahwinder, et al.
Publicado: (2011)

A panoramic view of RNA modifications: exploring new frontiers
por: Zhang, Zijun, et al.
Publicado: (2018)

Promising Antigens for the New Frontier of Targeted Immunotherapy in Multiple Myeloma
por: Cho, Shih-Feng, et al.
Publicado: (2021)

Frontiers in plant genetics
por: Hake, Sarah
Publicado: (2004)

Frontiers of marine science
por: Webb, Thomas J., et al.
Publicado: (2011)

Driving CARs to new places: locally produced BCMA CAR T cells to treat multiple myeloma
por: Sjöstrand, Maria, et al.
Publicado: (2023)

Tinea corporis in a wrestling team cheerleader()
por: McClanahan, C., et al.
Publicado: (2016)

New CAR Designs: Highlights From SOHO 2020
Publicado: (2021)

Multiple Myeloma: Risk Stratification and Toxicity Management
por: Richards, Tiffany, et al.
Publicado: (2018)

CAR T-Cell Therapy for Patients with Multiple Myeloma: Current Evidence and Challenges
por: Rendo, Matthew J, et al.
Publicado: (2022)

A Focus on CAR T-Cell Therapy and Bispecific Antibodies in Multiple Myeloma
por: Catamero, Donna, et al.
Publicado: (2022)

Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma
por: Roex, Gils, et al.
Publicado: (2020)

CAR-T cell therapy in multiple myeloma: Current limitations and potential strategies
por: Zhang, Xiaomin, et al.
Publicado: (2023)

The Role of Monoclonal Antibodies in the Era of Bi-Specifics Antibodies and CAR T Cell Therapy in Multiple Myeloma
por: Mohan, Meera, et al.
Publicado: (2021)

New bortezomib-based combination therapy for elimination of myeloma cells
por: Meister, S, et al.
Publicado: (2009)

Recent Advances in the Treatment Of Newly Diagnosed Multiple Myeloma
por: Libby, Edward, et al.
Publicado: (2020)

Novel Treatments for Patients With Relapsed/Refractory Multiple Myeloma
por: Rodriguez, Cesar, et al.
Publicado: (2023)

The New Frontier of Immunotherapy: Chimeric Antigen Receptor T (CAR-T) Cell and Macrophage (CAR-M) Therapy against Breast Cancer
por: Schepisi, Giuseppe, et al.
Publicado: (2023)

New Frontiers about the Role of Human Microbiota in Immunotherapy: The Immune Checkpoint Inhibitors and CAR T-Cell Therapy Era
por: Innao, Vanessa, et al.
Publicado: (2020)

Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond
por: Su, Christopher T., et al.
Publicado: (2021)

Road testing new CAR design strategies in multiple myeloma
por: Rana, Priyanka S., et al.
Publicado: (2022)

New frontiers in healthcare environmental hygiene: thoughts from the 2022 healthcare cleaning forum
por: Peters, Alexandra, et al.
Publicado: (2023)

Sequential CAR T cell and targeted alpha immunotherapy in disseminated multiple myeloma
por: Awuah, Dennis, et al.
Publicado: (2023)

Anti-BCMA CAR T-cell Therapy: Changing the Natural History of Multiple Myeloma
por: Puertas, Borja, et al.
Publicado: (2022)

CAR-T cell therapy for multiple myeloma: a practical toolkit for treatment in Brazil
por: Hungria, Vania, et al.
Publicado: (2023)

CAR T-cell therapy for triple-class exposed relapsed/refractory multiple myeloma
por: Cavo, Michele
Publicado: (2023)

Toward a new frontier on economic and technologic assessment in intensive care: the role of ethics
por: Coelho, CD, et al.
Publicado: (2003)

CAR T-Cells in Multiple Myeloma Are Ready for Prime Time
por: Rodríguez-Otero, Paula, et al.
Publicado: (2020)

Perspectives for the Use of CAR-T Cells for the Treatment of Multiple Myeloma
por: Jasiński, Marcin, et al.
Publicado: (2021)

CAR-T cell therapy in myeloma: hopes and hurdles
por: Harousseau, Jean Luc
Publicado: (2023)

New Drug Updates in Hematologic Malignancies: CAR-T, Targeted Therapeutics, and Other Agents
por: Harvey, R. Donald
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_rqn9u5fpkaummb87uojnaltf52